Abstract:The surge of SARS-CoV-2 Omicron infection in most Chinese residents at the end of 2022 provided a unique opportunity to understand how the immune system responds to the Omicron infection in a population with limited contact to prior SARS-CoV-2 variants. Moreover, whether the prototype SARS-CoV-2 booster vaccination could help induce the antibody against Omicron variants? Here, we tested the level of IgG, IgA, and IgM specific to the prototype SARS-CoV-2 spike RBD (Receptor Binding Domain) from the collected blood samples from 636 individuals. Sequential inoculation of different vaccines showed higher IgG levels after infection. As the antibody level against Omicron BA.5, BF.7, and XBB 1.5 of the individuals has highly positive correlation with the antibody level against prototype SARS-CoV2, the IgG level specific to the prototype SARS-CoV-2 spike RBD could also represent the IgG level against Omicron variants. Furthermore, the 4th booster vaccination could induce a comparable antibody level against prototype, Omicron BA.5, BF.7, and XBB 1.5 variants in the patients with 2 or 3-dose vaccination and protect people from being infected. In conclusion, these data suggest that the prototype SARS-CoV-2 booster vaccination helps induce a high level of antibody against prototype, BA.5, BF.7, and XBB 1.5 variants after Omicron infection. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was funded by the SARS-CoV2 Research and Control Project 2020 (Jack Ma Foundation), National Natural Science Foundation of China (82000941 to D.T.), Fundamental Research Funds for the Central Universities (WK5290000001 to Y.C., WK5290000002 to Y.Yao.). The study was also supported by Anhui Postdoctoral Scientific Program (D.T.). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee of The First Affiliated Hospital of University of Science and Technology of China gave ethical approval for this work. Approval number: 2023-KY-001 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors. All data produced in the present work are contained in the manuscript.

Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study

Proteomics Investigation of Diverse Serological Patterns in COVID-19

Antibody Response and Cross-Neutralization after Omicron BA.2 Infection

Host Protection Against Omicron BA.2.2 Sublineages by Prior Vaccination in Spring 2022 COVID-19 Outbreak in Shanghai

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Vaccination Effects on Post-Infection Outcomes in the Omicron BA.2 Outbreak in Shanghai

Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study

Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants

[Periodic Dynamic Observation and Analysis of Cellular and Humoral Immunity Indexes of Adults Infected with Omicron BA.1].

Neutralizing Antibody Responses in Patients with Hematological Malignancies after Omicron Infection: A Multicenter, Prospective Cohort Study in China

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

A survey and antibody test following the surge of SARS-CoV-2 Omicron infection in China

Longitudinal Neutralization Activities on Authentic Omicron Variant Provided by Three Doses of BBIBP‐CorV Vaccination During One Year

Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight Against Omicron Subvariant BA.2 after COVID-19 Vaccination.

Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination

Drastic Decline in Sera Neutralization Against SARS-CoV-2 Omicron Variant in Wuhan COVID-19 Convalescents

Profiling B cell immune responses to identify neutralizing antibodies from convalescent COVID 19 patients

Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection

Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai

A community study of neutralizing antibodies against SARS-CoV-2 in China

Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population